Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sarah Goldberg MD, MPH

Sarah B. Goldberg MD, MPH

Associate Professor of Medicine (Medical Oncology), Yale School of Medicine/Yale Cancer Center, New Haven, Connecticut

Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. She specializes in the treatment of thoracic malignancies, including lung cancer, mesothelioma, and thymoma. Her research interests include personalized medicine and immunotherapy for non–small cell lung cancer and identification of biomarkers that predict response to treatment.

Disclosures

  • Research Funding: AstraZeneca; Boehringer Ingelheim; Mirati
  • Advisory Board and Consultancy: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Amgen; Blueprint Medicines; Sanofi Genzyme; Daiichi-Sankyo; Takeda; Janssen; Summit Therapeutics; Merck; Regeneron

Recent Contributions to PracticeUpdate:

  1. Amivantamab Plus Lazertinib for EGFR-Mutant Lung Cancer Following Progression on Osimertinib
  2. Comparative Effectiveness of Chemoimmunotherapy vs Immunotherapy for Non–Small Cell Lung Cancer
  3. Sotorasib for KRAS G12C-Mutated Lung Cancer
  4. ASCO 2021: Abstract Recommendations From Dr. Sarah Goldberg for Lung Cancer
  5. Pemetrexed Plus Platinum ± Pembrolizumab in Patients With Previously Untreated Metastatic Nonsquamous NSCLC
  6. Pembrolizumab vs Chemotherapy for PD-L1–High Metastatic NSCLC
  7. CNS Disease Control in Patients With NSCLC Brain Metastases Treated With ICIs Plus Cranial Radiotherapy
  8. High-Risk Clinicopathologic Features and Outcomes Among Patients Receiving Adjuvant Chemotherapy for Early-Stage Non-Small Cell Lung Cancer
  9. Erlotinib vs Etoposide/Cisplatin With Radiotherapy in Unresectable Stage III EGFR Mutation–Positive NSCLC
  10. 2020 Top Stories in Oncology: Osimertinib in Early-Stage EGFR-Mutant NSCLC

Most Read This Week

Recently Updated